Baidu
map

干货:24种皮肤病外用药膏

2022-01-06 店讯通 店讯通

当出现皮肤病时可选择口服药物、也可选择外用药或是其他辅助方式,目前,外用药仍是治疗皮肤病的主要方法之一。24种常见皮肤科外用药大盘点!

当出现皮肤病时可选择口服药物、也可选择外用药或是其他辅助方式,目前,外用药仍是治疗皮肤病的主要方法之一。

很多患者面对琳琅满目外用药膏却不知道什么选择,今天,就跟大家讲解这24种常见外用药膏的功效及联合用药。

 

图片

 

1.复方醋酸地塞米松乳膏(皮炎平)

适应症:主要用于过敏性和自身免疫性炎症性疾病。如局限性瘙痒症、神经性皮炎、接触性皮炎、脂溢性皮炎、慢性湿疹等。

用法用量:外用。一日1~2次。

联合用药:西替利嗪/氯雷他定+复方地塞米松乳膏

不良反应:长期大量使用可继发细菌、真菌感染,局部可发生痤疮、酒渣样皮炎、皮肤萎缩及毛细血管扩张,并可有瘙痒、色素沉着、颜面红斑、创伤愈合障碍等反应。

禁忌:1、患处有破溃、化脓或有明显渗出者禁用。2、病毒感染者禁用。

2.复方硝酸咪康唑乳膏

适应症:用于体股癣、足癣等,也用于丘疹性荨麻疹、湿疹、皮肤瘙痒症等。用于各种真菌感染。

联合用药:

手癣:复方硝酸咪康唑乳膏(封包疗法)+氟康唑+珊瑚癣净

体、股癣:复方硝酸咪康唑乳膏+口服氟康唑(疗程1~4周)

指甲癣:复方硝酸咪康唑乳膏+口服氟康唑+亮甲(疗程6个月)

足癣:足光粉+复方硝酸咪康唑乳膏+斯皮仁诺(疗程1个月)

荨麻疹:复方硝酸咪康唑软膏+盐酸西替利嗪片/氯雷他定片+肤痒颗粒+维生素C

湿疹:复方硝酸咪康唑软膏+消风止痒颗粒/湿毒清+维生素C

不良反应:偶见过敏反应。

3.酮康唑乳膏

适应症:体股癣、手足癣、花斑癣、头癣、须癣、甲癣;皮肤、指(趾)甲念珠菌病;口角炎、外耳炎。由革兰阳性细菌引起的继发性感染。

用法用量:外用。早晚各1次,症状消失后应继续用药10天,以防复发。

联合用药:

手癣:酮康唑乳膏(封包疗法)+口服氟康唑+珊瑚癣净

体、股癣:酮康唑乳膏+口服氟康唑( 疗程1~4周)

指甲癣:酮康唑乳膏+口服氟康唑+亮甲( 疗程6个月)

足癣:足光粉+酮康唑乳膏+斯皮仁诺 (疗程1个月)

不良反应:偶见过敏反应。

4.曲安奈德益康唑乳膏

适应症:用于各种真菌感染、皮炎、湿疹。

联合用药:

手癣:曲安奈德益康唑乳膏(封包疗法)+口服氟康唑+珊瑚癣净

体、股癣:曲安奈德益康唑乳膏+口服氟康唑(疗程1~4周)

指甲癣:曲安奈德益康唑乳膏+口服氟康唑+亮甲(疗程6个月)

足癣:足光粉+曲安奈德益康唑乳膏+斯皮仁诺 (疗程1个月)

过敏性皮炎:西替利嗪+曲安奈德益康唑乳膏(疗程2~4周)

不良反应:过敏反应,皮肤萎缩,色素沉着,局部毛细血管扩张。

5.丹皮酚软膏

适应症:抗过敏,消炎止痒。用于各种湿疹、皮炎、虫咬性皮炎、皮肤瘙痒、过敏性鼻炎。

联合用药:

过敏性皮炎:西替利嗪+丹皮酚软膏

过敏性鼻炎:通窍鼻炎片+氯雷他定+丹皮酚软膏

虫咬性皮炎:消炎粉/消炎止痒水+丹皮酚软膏

6.维A酸乳膏

适应症:用于寻常痤疮、扁平疣、黏膜白斑、毛发红糠疹、毛囊角化病及银屑病的辅助治疗。

用法用量:外用。

寻常痤疮:每晚1次,于睡前将药轻轻涂于患处。银屑病、鱼鳞病等皮疹位于遮盖部位的可一日1-3次或遵医嘱。用毕应洗手。若白天用药可选择过氧苯甲酰凝胶或复方硫酸铜药膏。

不良反应:外用本品可能会引起皮肤刺激症状,如灼感、红斑及脱屑,可能使皮损更明显,但同时表明药品正在起作用,不是病情的加重。

皮肤多半可适应及耐受,刺激现象可逐步消失。若刺激现象持续或加重,可在医师指导下间歇用药,或暂停用药。

7.老鹳草软膏

适应症:用于细菌感染性皮肤病。脓疱疮、毛囊炎、足癣继发化脓感染、湿疹继发感染及表浅局限性感染。

用法:一日2次,外用。

联合用药:

湿疹、皮炎:西替利嗪/氯雷他定+老鹳草软膏

烧烫伤:老鹳草软膏+百多邦+口服消炎药

禁忌:对喹诺酮过敏者禁用。

8.复方双花藤止痒擦剂

适应症:用于各种湿疹、皮痒导致的皮肤瘙痒。

联合用药:丁酸氢化可的松乳膏+复方双花藤止痒擦剂

9.盐酸特比萘芬乳膏

 

适应症:用于治疗手癣、足癣、体癣、股癣及花斑癣等。

联合用药:盐酸特比奈芬乳膏+百癣夏塔热片

不良反应:偶在用药部位出现发红、发痒或蛰刺感,但很少要因此停药。

10.卡泊三醇软膏

适应症:用于寻常型银屑病的局部治疗。脓疱疮、毛囊炎、足癣继发化脓感染、湿疹继发感染及表浅局限性感染。

用法用量:将本品少量涂于患处皮肤,每日1~2次。推荐在治疗初期每日给药2次,适当时可减为每日1次给药。每周最大用量不应超过100g。

11.喷昔洛韦乳膏

适应症:用于口唇或面部单纯疱疹、生殖器疱疹。

用法:外用每日4~5次。

不良反应:轻度灼痛瘙痒及皮疹。

12.阿昔洛韦凝胶

适应症:用于单纯疱疹或带状疱疹感染。

用法:每2小时一次,一日4~6次,共7日。

不良反应:轻度灼痛瘙痒及皮疹。

13.糠酸莫米松乳膏

适应症:用于湿疹、神经性皮炎、异位性皮炎及皮肤瘙痒症。

用法:每日1次。

禁忌:皮肤破损者禁用。

不良反应:偶有灼热感,长期使用出现色素沉着,血管扩张,继发感染或皮肤轻度萎缩。

14.曲咪新乳膏

适应症:用于湿疹、各种皮炎、足癣、体癣股癣、手癣。

用法:外用,一日2~3次。

15.氧氟沙星凝胶

适应症:用于细菌感染性皮肤病。脓疱疮、毛囊炎、湿疹继发感染、疖肿、外伤感染。

用法用量:外用,一日2次。

联合用药:氧氟沙星凝胶+盐酸左氧氟沙星片/阿奇霉素

禁忌:对喹诺酮过敏者禁用。

16.丁酸氢化可的松乳膏

适应症:用于过敏性皮炎、脂溢性皮炎、过敏性湿疹及苔藓样瘙痒。

用法:一日2次。

不良反应:长期使用可致皮肤萎缩,毛细血管扩张,色素沉着及继发感染。

17.硝酸咪康唑乳膏

适应症:体股癣、手足癣、花斑癣、头癣、须癣、甲癣;皮肤、指(趾)甲念珠菌病;口角炎、外耳炎。由革兰阳性细菌引起的继发性感染。

用法用量:外用。早晚各1次,症状消失后应继续用药10天,以防复发。

18.醋酸曲安奈德益康唑软膏

适应症:用于伴有真菌感染或有真菌感染倾向的皮炎、湿疹;由皮肤癣菌、酵母菌和霉菌所致的炎症性皮肤真菌病。如足癣、体癣、花斑;尿布性皮炎;念珠菌性口角炎;甲沟炎;由真菌、细菌所致的皮肤混合感染。

用法用量:每日早晚各一次。

19.甲硝唑凝胶

适应症:用于各种炎症性皮炎、酒糟鼻。

联合用药:抗菌消炎药+甲硝唑凝胶+龙胆紫

不良反应:偶见皮肤干燥、烧灼感等过敏反应。

20.联苯苄唑乳膏

适应症:用于各种真菌感染。

联合用药:

手癣:联苯苄唑乳膏(封包疗法)+氟康唑+珊瑚癣净

体、股癣:联苯苄唑乳膏+口服氟康唑 (疗程1~4周)

指甲癣:联苯苄唑乳膏+口服氟康唑+亮甲( 疗程6个月)

足癣:足光粉+联苯苄唑乳膏+斯皮仁诺(疗程1个月)

不良反应:偶见过敏反应。

21.硝酸益康唑喷剂

适应症:用于各种真菌感染。

联合用药:

足癣:足光粉+曲安奈德益康唑乳膏+硝酸益康唑喷剂

花斑癣:曲安奈德益康唑乳膏+硝酸益康唑喷剂

头癣:灰黄霉素+硝酸益康唑喷剂+复方酮康唑发用洗剂

体、股癣:口服氟康唑+硝酸益康唑喷剂

不良反应:偶见过敏反应。

22.无极膏

适应症:用于消炎、镇痛、止痒、抗菌。

联合用药:

虫咬性皮炎:阿莫西林+无极膏

丘疹性荨麻疹:氯雷他定+无极膏

不良反应:偶见皮肤刺激症。

23.盐酸特比萘芬喷剂

 

适应症:用于治疗手癣、足癣、体癣、股癣及花斑癣等。

不良反应:偶见皮肤刺激如烧灼感,或过敏反应如皮疹、瘙痒等。

注意:孕妇及哺乳期妇女慎用;避免接触眼睛和其他黏膜(如口、鼻等);涂抹后不必包扎;不得用于皮肤破溃处。

24.肤痔清软膏

适应症:由于各种手足癣,体、股癣,内外痔,带下病。

联合用药:

内外痔:痔速宁/六味消痔/痔炎消/裸花紫珠+肤痔清软膏

带下病:盐酸左氧氟沙星+妇炎净/妇炎康/抗宫炎+ 肤痔清软膏

不良反应:偶见过敏反应。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2023-11-15 katherine4567 来自广东省

    赞,感谢整理和分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-07 ms8000001859380106

    正好需要

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-07 ms8000000272250697

    厉害厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-07 1244c0ebm28暂无昵称

    不错不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-06 ms3000001138543316

    受益匪浅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2168614, encodeId=3457216861478, content=赞,感谢整理和分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa24535, createdName=katherine4567, createdTime=Wed Nov 15 09:39:33 CST 2023, time=2023-11-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1826154, encodeId=16aa18261541d, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 12 07:34:18 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182005, encodeId=b4671182005a4, content=正好需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0686454051, createdName=ms8000001859380106, createdTime=Fri Jan 07 22:07:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181965, encodeId=2cd6118196588, content=厉害厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72815515020, createdName=ms8000000272250697, createdTime=Fri Jan 07 20:21:16 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181723, encodeId=7a821181e231c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Jan 07 08:46:34 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181566, encodeId=092711815667e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f5f5472733, createdName=ms3000001138543316, createdTime=Thu Jan 06 22:03:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181560, encodeId=a0ba118156095, content=👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcef1883891, createdName=ms56259741407129675302, createdTime=Thu Jan 06 21:55:39 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-06 ms56259741407129675302

    👍👍

    0

Baidu
map
Baidu
map
Baidu
map